Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gravidol is a branded formulation of labetalol hydrochloride, an alpha- and beta-adrenergic receptor blocker manufactured by Mercury Laboratories. It is primarily used to manage hypertension, including hypertensive emergencies and high blood pressure during pregnancy (preeclampsia). By blocking both alpha-1 and non-selective beta-adrenergic receptors, it reduces peripheral vascular resistance and slows heart rate, effectively lowering blood pressure while maintaining cardiac output. It is available in oral tablet and injectable forms, and is specifically marketed within Mercury Laboratories' focus on mother and child healthcare.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gravidol.